Raising my target price on Incyte to $120 a share after 58.5% gain in last 3 months

Raising my target price on Incyte to $120 a share after 58.5% gain in last 3 months

This page is for Subscribers.

We’ll share all of our Posts and our Live Public Portfolios with you!

Sign Up for a subscription and you can view everything on the Juggling With Knives website. (If you’ve purchased the book, you’ve earned a free subscription. Use the Coupon Code in the book to start your one-year FREE subscription).

Plus, you’ll get Jim’s Volatility Email Update each evening at 8:00pm.

SignUpButton200

Trump administration picks five coronavirus vaccine efforts to receive big government funding

Trump administration picks five coronavirus vaccine efforts to receive big government funding

This page is for Subscribers.

We’ll share all of our Posts and our Live Public Portfolios with you!

Sign Up for a subscription and you can view everything on the Juggling With Knives website. (If you’ve purchased the book, you’ve earned a free subscription. Use the Coupon Code in the book to start your one-year FREE subscription).

Plus, you’ll get Jim’s Volatility Email Update each evening at 8:00pm.

SignUpButton200

Stock Pick of the Day: Acadia Pharmaceuticals (ACAD)

Stock Pick of the Day: Acadia Pharmaceuticals (ACAD)

This page is for Subscribers.

We’ll share all of our Posts and our Live Public Portfolios with you!

Sign Up for a subscription and you can view everything on the Juggling With Knives website. (If you’ve purchased the book, you’ve earned a free subscription. Use the Coupon Code in the book to start your one-year FREE subscription).

Plus, you’ll get Jim’s Volatility Email Update each evening at 8:00pm.

SignUpButton200

More headroom for biotech sector–and heads up on a coming pick

More headroom for biotech sector–and heads up on a coming pick

This page is for Subscribers.

We’ll share all of our Posts and our Live Public Portfolios with you!

Sign Up for a subscription and you can view everything on the Juggling With Knives website. (If you’ve purchased the book, you’ve earned a free subscription. Use the Coupon Code in the book to start your one-year FREE subscription).

Plus, you’ll get Jim’s Volatility Email Update each evening at 8:00pm.

SignUpButton200

FDA and Nektar both shock on company’s opioid drug candidate; I’d buy more on weakness

FDA and Nektar both shock on company’s opioid drug candidate; I’d buy more on weakness

This page is for Subscribers.

We’ll share all of our Posts and our Live Public Portfolios with you!

Sign Up for a subscription and you can view everything on the Juggling With Knives website. (If you’ve purchased the book, you’ve earned a free subscription. Use the Coupon Code in the book to start your one-year FREE subscription).

Plus, you’ll get Jim’s Volatility Email Update each evening at 8:00pm.

SignUpButton200